Highest-materiality recent filing
LifeVantage Q4 revenue down 23% to $42.4M; FY revenue down 20% to $182.6M
Q4 revenue $42.4M (-23.1% YoY); Americas -24.8%, APAC/Europe -16.9%.
LifeVantage adopts 2026 New Employee LTIP, reserving 1.5M shares for new-hire equity awards
Board approved 2026 New Employee Long-Term Incentive Plan on July 31, 2026.
LifeVantage Q3 revenue drops 25%; EPS falls to $0.11; guidance lowered
Revenue $43.7M, down 25.2% YoY; Americas down 28.9%, Asia/Pacific & Europe down 7.7%.
LifeVantage names Terrence Moorehead CEO; current CEO Steve Fife retiring Apr 30
Steve Fife retires as President and CEO effective April 30, 2026; transition agreement with advisory through Sept 11, 2026.
LifeVantage Q2 revenue drops 27.8% to $48.9M; CEO Fife to retire in April
Revenue $48.9M, down 27.8% YoY; Americas revenue fell 32.6%.
LifeVantage CMO and CIO resign, effective Dec 12 and Dec 24, 2025
CMO Julie Boyster resigns effective December 12, 2025 to pursue other opportunities.
LifeVantage FY2026 annual meeting results: all proposals approved
All seven director nominees elected; Beindorff, Greer, Lewis received >1.9M against votes and 1.87M broker non-votes.
LifeVantage Q1 FY2026 revenue $47.6M (+0.7%), EPS $0.17 vs $0.14 a year ago
Net income $2.2M ($0.17 diluted EPS); adjusted EPS $0.18 vs $0.15.
LifeVantage Q4 revenue $55.1M (+12.6% YoY); full-year EPS $0.75 vs $0.23
Q4 revenue $55.1M (+12.6%); net income $0.15 diluted EPS (adjusted $0.17).
LifeVantage Q3 revenue $58.4M (+21% YoY); EPS $0.26 vs $0.13
Net income $3.5M ($0.26 diluted EPS) vs $1.7M ($0.13) a year ago; adjusted EPS also $0.26 vs $0.21.
LifeVantage Q2 revenue up 31% to $67.8M; raises FY2025 guidance
Revenue $67.8M (+31.3% YoY); Americas +46.3%, APAC/Europe -15.5%.
LifeVantage eliminates Series A Preferred Stock after Rights Agreement expired
Rights Agreement expired Aug 28, 2024; stock purchase rights terminated.
LifeVantage annual meeting results: all eight directors elected, say-on-pay approved
All 8 director nominees elected; votes ranged from 5.59M to 6.19M for.
LifeVantage Q1 revenue falls 8.1% to $47.2M; net income rises to $0.14 diluted EPS
Net income of $0.14 diluted EPS vs $0.05 a year ago; adjusted EPS $0.15 vs $0.13.
LifeVantage Q4 rev down 9.8% to $48.9M; FY adj EPS $0.59; FY25 guidance $200-210M
Q4 GAAP EPS $0.10; adjusted EPS $0.14; revenue down 9.8% YoY to $48.9M.
Erin Brockovich resigns from LifeVantage board; Rajendran Anbalagan appointed
Erin Brockovich resigned from LifeVantage board effective Aug 26, 2024; not due to any disagreement.
LifeVantage Q3 revenue falls 10.2% to $48.2M; guidance cut; adjusted EBITDA up 55%
Revenue $48.2M, down 10.2% YoY; Americas -5.9%, Asia/Pacific & Europe -22.4% (constant currency -16.1%).
LifeVantage enters $5M revolving credit facility with Bank of America, matures 2027
Revolving line of credit up to $5,000,000 with Bank of America; interest at Term SOFR + 2.00% (floor 0.00%).
LifeVantage appoints Dayton Judd to board under cooperation agreement with activist investors
Appointed Dayton Judd to Board; Board size increased by one seat.
Revenue $51.6M (-3.8% YoY); Americas -1.6%, Asia/Pacific & Europe -10.0% (-8.0% constant currency).
LifeVantage shareholders re-elect all seven incumbent directors, approve stockholder rights plan
Final certified results confirm all 7 incumbent directors re-elected; each received majority support.
LifeVantage Q1 FY24 revenue $51.4M (-0.8% YoY); adj. EBITDA +41%, adj. EPS $0.13
Revenue $51.4M, down 0.8% YoY (ex-FX -0.2%). Americas +5.9%, US +6.5%; Asia/Pacific & Europe -16.6% (-14.6% constant currency).
LifeVantage shareholders elect company's director slate, reject dissident nominees
All seven company-nominated directors elected; dissident candidates Bradley Radoff (3.1M for vs 6.1M withhold), Dayton Judd, and Michael Lohner defeated.
LifeVantage adopts limited duration stockholder rights plan expiring Aug 2024, with 12% trigger
One right per common share outstanding as of Sept 11, 2023 record date; exercise price $20 per right.
Q4 GAAP EPS $0.15 vs loss $0.11 YoY; adjusted EPS $0.17 vs $0.01; revenue $54.2M (+6.4% YoY).
LifeVantage confirms Bradley L. Radoff plans to nominate three directors for 2024 annual meeting
Bradley L. Radoff notified LifeVantage of intent to nominate three candidates to the Board at fiscal 2024 annual meeting.
LifeVantage extends stock repurchase program to Dec 31, 2026; authorizes 10b5-1 plan
Board extended stock repurchase program through December 31, 2026.
LifeVantage Q3 revenue up 7.5% to $53.7M; guides FY23 rev $209-212M
Revenue $53.7M (+7.5% YoY; +10.4% constant currency). Americas +18.2%, APAC/Europe -14.2%.
LifeVantage appoints Deloitte & Touche as new independent auditor
Audit Committee engaged Deloitte & Touche as new independent registered public accounting firm effective April 13, 2023.
LifeVantage COO Matt Cooley resigns, effective April 4, 2023
COO Matt Cooley voluntarily resigns; last day of employment is April 4, 2023.
LifeVantage auditor WSRP declines reappointment for FY2023; no disagreements cited
WSRP notified LifeVantage on Feb 15, 2023 it will not stand for reappointment for FY ending June 30, 2023.
LifeVantage Q2 revenue $53.7M (+2.8% YoY); net loss $0.08 EPS; guides FY rev $202-212M
Revenue $53.7M, up 2.8% YoY (7.4% constant currency); Americas up 14.4%, Asia/Pac & Europe down 20.2%.
LifeVantage adopts new distributor compensation plan effective March 1, 2023
New plan initially applies to US, Australia, New Zealand, and Japan markets.
LifeVantage shareholders elect all seven directors, approve say-on-pay, auditor, and LTIP amendment
All seven director nominees elected: Beindorff, Brockovich, Fife, Greer, Latham, Lewis, Mauro.
LifeVantage shareholders elect all six director nominees at FY2022 annual meeting
Voter turnout 66.63% (8,369,050 of 13,235,944 shares represented).
LifeVantage Q1 revenue $51.8M (-2.7% YoY); adj. EPS $0.06 vs $0.23; dividend $0.03
Revenue $51.8M, down 2.7% YoY; constant-currency revenue up 2.3%.
LifeVantage Q4 revenue down 7% to $50.9M; GAAP EPS loss $0.11 vs $0.35 profit YoY
Q4 revenue $50.9M (-7% YoY); Americas down 10.5%, Asia/Pacific & Europe up 0.7% (up 12.8% ex-FX).
LifeVantage Q3 revenue down 3%; cuts FY2022 guidance; initiates $0.03 dividend
Q3 revenue $50.0M, down 3% YoY (less than 1% ex-FX); EPS diluted $0.09, adjusted $0.12.
LifeVantage Chief Sales Officer Justin Rose departs effective March 7, 2022
Justin Rose's employment as Chief Sales Officer ended March 7, 2022.
LifeVantage appoints Cindy Latham to Board of Directors effective Feb 17, 2022
Cindy Latham appointed to the Board and Compensation Committee, term expires at fiscal 2023 annual meeting.
LifeVantage Q2 revenue $52.2M, down 11.6% YoY; cuts FY2022 guidance
Revenue $52.2M, down 11.6% YoY; EPS $0.01 diluted; adjusted EPS $0.05.
LifeVantage annual meeting elects all six director nominees; say-on-pay and auditor ratified
All six director nominees elected with >4.5M votes for each; broker non-votes ~3.73M.
LifeVantage Q1 FY2022 revenue $53.2M (-2.9% YoY); adjusted EPS $0.23 (-8%)
Revenue of $53.2M, down 2.9% YoY; Americas -5.8%, Asia/Pacific & Europe +3.9%.
LifeVantage appoints Carl Aure as CFO; Steven Fife remains CEO
Carl Aure appointed CFO effective Oct 25, 2021, replacing Steven Fife who remains CEO.
LifeVantage Q4 revenue $54.8M (-7.7% YoY), adj EPS $0.31 (+10.7% YoY); FY22 guidance $225-235M
Q4 revenue $54.8M, down 7.7% YoY; Americas -9.6%, Asia/Pacific & Europe -3.3%.
Director Vinayak Hegde will not stand for re-election at LifeVantage fiscal 2022 annual meeting
Vinayak Hegde informed LifeVantage on Aug 12, 2021, he will not stand for re-election.
On August 23, 2024, Erin Brockovich, a member of the Board of Directors (the “Board”) of LifeVantage Corporation (the “Company”), notified the Company of her resignation as a member of the Board and any committees of the Board, effective August 26, 2024.
On August 26, 2024, the Board, based on the recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Rajendran Anbalagan as a member of the Board, effective immediately.
Effective as of February 14, 2024, Mr. Judd has been appointed as a member of the Board.
On March 20, 2023, LifeVantage Corporation (the “Company”) received notice from Chief Operating Officer Matt Cooley of his voluntary resignation from the Company.
The employment of Justin Rose, LifeVantage Corporation’s Chief Sales Officer, ended effective on March 7, 2022.
the appointment of Cynthia Latham as a member of the Board
On October 25, 2021, the Company announced the appointment of Carl Aure as its Chief Financial Officer, effective immediately.
Steven R. Fife will step down from his role as the Company’s Chief Financial Officer effective immediately.
On August 12, 2021, Vinayak Hegde, a member of the Board of Directors (the “Board”) of LifeVantage Corporation (the “Company”), informed the Company that, due to his other commitments, he has decided not to stand for re-election as a director of the Company at the fiscal 2022 annual meeting of stockholders expected to be held on or about November 11, 2021.
Max materiality 0.80 · Median 0.60 · Most common event earnings